Anticoagulation Reduces Subclinical Leaflet Thrombosis After TAVI
According to the European Society of Cardiology, non-vitamin K antagonist oral anticoagulant (NOAC) therapy reduces imaging signs of clot formation on new heart valves by 45% compared with antiplatelet therapy following transcatheter aortic valve implantation (TAVI), without compromising patient safety. ACASA-TAVI Trial Results Presented at ESC Congress 2026 The ACASA-TAVI trial, presented during a Hot … Read more